Dafinchi AI

BCRX

Healthcare

Approximately 90% of ORLADEYO revenue was generated in the U.S., totaling $140.3 million.
Expected net interest savings of approximately $90 million over the life of the loan due to prepayments.
Generated $45 million cash in Q2 before debt prepayment; paid down $125 million in term loan principal in April and July, reducing debt to $199 million.
Non-GAAP operating expenses were $106.4 million, up from $87.4 million in Q2 2024, driven by continued R&D investments.
Non-GAAP operating profit was $57 million, and non-GAAP net income was $32.3 million, resulting in EPS of $0.15.
Projected to reach $700 million in cash by 2027, with plans to actively deploy capital into value-creating opportunities.
Total revenue for Q2 2025 was $163.4 million, with $156.8 million from ORLADEYO, representing 45% year-over-year growth.

MDGL

Healthcare

Madrigal Pharmaceuticals reported net sales of $212.8 million in Q2 2025, a 55% increase quarter-over-quarter.
R&D expenses decreased to $54.1 million from $71.1 million year-over-year due to lower clinical trial costs.
SG&A expenses increased to $196.9 million from $105.4 million year-over-year, driven by commercial launch activities.
The company ended Q2 2025 with $802 million in cash and equivalents and secured a $500 million senior secured credit facility.
U.S. Rezdiffra net sales are annualizing at over $800 million.

Earnings Feed